Get the Stockscreener App
125.77
0.55%
0.69
Insmed Inc stock is traded at $125.77, with a volume of 1.12M.
It is up +0.55% in the last 24 hours and up +15.79% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$125.08
Open:
$125.22
24h Volume:
1.12M
Relative Volume:
0.32
Market Cap:
$27.47B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-21.90
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
+1.64%
1M Performance:
+15.79%
6M Performance:
-23.73%
1Y Performance:
-5.15%
1-Day Range:
$124.82
$127.20
1-Week Range:
$124.60
$131.10
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
125.77 | 27.32B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares - Quiver Quantitative
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Director Melvin Sharoky Reports Sale of 5,000 Shares via Padonia, LLC - Kalkine Media
Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing - marketscreener.com
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC - Stock Titan
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story - simplywall.st
BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - stocktwits.com
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Insmed CMO Martina Flammer sells $3.49m in company stock By Investing.com - Investing.com Australia
Insmed CMO Martina Flammer sells $3.49m in company stock - Investing.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $220 - Moomoo
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc. - MarketBeat
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC - MarketBeat
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
INSM|Insmed Inc|Price:123.740|Chg%:-2.590 - TradingKey
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - moomoo.com
FY2026 Earnings Forecast for Insmed Issued By HC Wainwright - MarketBeat
Handelsbanken Fonder AB Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares - MarketBeat
Insmed Insider Sold Shares Worth $31,964,810, According to a Recent SEC Filing - marketscreener.com
Insmed Chief Operating Officer Sold Shares Worth Over $31M - TradingView
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for Insmed - MarketBeat
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 - kalkine.ca
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
INSM (INSM) insider notice covers 239,850 shares and prior sales data - Stock Titan
INSM Maintained by JP Morgan -- Price Target Lowered to $175 - GuruFocus
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
INSM Reiterates by Truist Securities -- Price Target Raised to $195 - GuruFocus
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
H.C. Wainwright reiterates Buy on Insmed stock, $220 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Insmed stock, $220 target - Investing.com India
High Growth Tech Stocks in the US to Watch - simplywall.st
Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed (NASDAQ:INSM) Posts Earnings Results - MarketBeat
Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile - simplywall.st
Insmed Insider Sold Shares Worth $3,494,838, According to a Recent SEC Filing - marketscreener.com
INSM Maintained by Guggenheim -- Price Target Lowered to $205 - GuruFocus
Insmed slips as investors digest a sharp post-earnings rally - Quiver Quantitative
INSM Maintained by Wells Fargo -- Price Target Raised to $169 - GuruFocus
Insmed Outlook Strengthens After Q2 Results, RBC Says - Yahoo Finance
What Insmed Stock’s Premium Is Actually Buying - Trefis
INSM Maintained by Evercore ISI Group -- Price Target Raised to $170 - GuruFocus
Has Insmed (INSM) Risen Above Fair Value After Its 3 Year Run? - Yahoo Finance
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):